Skyrizi

Drug Overview

Skyrizi is a high-potency BIOLOGIC and a sophisticated IMMUNOMODULATOR within the IMMUNOLOGY drug category. As a first-in-class TARGETED THERAPY, it is a humanized MONOCLONAL ANTIBODY that selectively inhibits Interleukin-23 (IL-23).

In the clinical landscape of 2024–2026, Skyrizi has emerged as a cornerstone treatment for chronic inflammatory conditions of the skin, joints, and gastrointestinal tract. By precisely blocking a specific “master switch” of the immune system, it allows for high rates of disease clearance and mucosal healing while minimizing broader systemic suppression.

• Generic Name: Risankizumab-rzaa
• US Brand Name: Skyrizi
• Route of Administration: Intravenous (IV) Infusion (Induction) and Subcutaneous (SC) Injection (Maintenance)
• FDA Approval Status: FDA-approved for adults with moderate-to-severe plaque psoriasis, active psoriatic arthritis, and moderate-to-severe Crohn’s disease or ulcerative colitis.
  
  Looking for clinical details on Skyrizi? As a highly effective Interleukin-23 Inhibitor, it is specifically indicated for Crohn’s Disease, Psoriasis, PsA. Read our full medical guide for patients and providers.

What Is It and How Does It Work? (Mechanism of Action)

Skyrizi functions through SELECTIVE CYTOKINE INHIBITION, specifically targeting the p19 subunit of the Interleukin-23 (IL-23) cytokine.

Molecular and Cellular Level Action

1. Selective Binding: Skyrizi binds with high affinity to the p19 subunit of the IL-23 protein. IL-23 is a key messenger molecule that tells the immune system to maintain a state of chronic inflammation.
2. Receptor Blockade: By binding to the p19 subunit, Skyrizi prevents IL-23 from connecting with its receptors on the surface of T-cells (specifically Th17 cells).
3. Halting the Cascade: Without the IL-23 signal, Th17 cells are not activated and cannot produce secondary inflammatory chemicals like IL-17 or TNF.
4. Tissue Restoration: In Psoriasis, this stops the overproduction of skin cells. In Crohn’s Disease, it stops the immune system from attacking the intestinal lining, promoting “mucosal healing.”
5. Prevention of Systemic Damage: Unlike older therapies that block multiple pathways (like IL-12 and IL-23), Skyrizi’s focus on the p19 subunit leaves other parts of the immune system (like the IL-12 pathway needed for viral defense) more intact, reducing the risk of systemic damage to the body’s natural defenses.

FDA-Approved Clinical Indications

Primary Indication

• Plaque Psoriasis: For adults with moderate-to-severe disease who are candidates for systemic therapy or phototherapy.
• Psoriatic Arthritis (PsA): For the treatment of active PsA in adults.
• Crohn’s Disease (CD): For the treatment of moderately to severely active disease in adults.
• Ulcerative Colitis (UC): Approved in 2024 for moderately to severely active disease in adults.

Other Approved & Off-Label Uses

While the current focus is on the indications above, research in 2025–2026 is exploring:

• Pediatric Psoriasis: Actively researched for younger populations.
• Ankylosing Spondylitis: Investigated for patients who do not respond to TNF blockers.

Primary Immunology Indications

• IL-23 Pathway Modulation: Specifically silencing the “IL-23/Th17 axis” to restore immune homeostasis.
• Mucosal Healing: Directly targeting the cytokines responsible for gut wall erosion in IBD.

Dosage and Administration Protocols

Skyrizi follows a “Load and Maintain” strategy. For IBD (Crohn’s/UC), the protocol is unique because it starts with hospital-based IV infusions before moving to home-based injections.

Dose Adjustments and Specific Protocols:

• IV Induction: The initial 600 mg doses must be administered by a healthcare professional over at least one hour.
• On-Body Injector: Maintenance doses for Crohn’s/UC are often delivered via a hands-free “On-Body Injector” that adheres to the skin.
• Storage: All SC forms must be refrigerated. Let the medication reach room temperature for 30–90 minutes before use.

Clinical Efficacy and Research Results

Efficacy was established through the UltIMMa (Psoriasis), KEEPsAKE (PsA), and ADVANCE/MOTIVATE (Crohn’s) trials.

Precise Numerical Data

• Skin Clearance (PASI 90): In clinical trials, approximately 75% of psoriasis patients achieved 90% skin clearance (PASI 90) by week 16, and over 50% achieved PASI 100 (total clearance).
• Crohn’s Remission: In the ADVANCE study, 45% of patients achieved clinical remission at week 12, with significant improvements in endoscopic “mucosal healing” compared to placebo.
• Joint Response (ACR20): Roughly 51% to 57% of PsA patients achieved an ACR20 response by week 24.
• Durability: 2026 real-world data shows that over 80% of patients who achieved clear skin at one year maintained those results through three years of therapy.

Safety Profile and Side Effects

Skyrizi is generally well-tolerated due to its high molecular specificity.

Common Side Effects (>10%)

• Upper Respiratory Infections: Common cold, sore throat, or sinus congestion.
• Headache: Often mild and transient.
• Fatigue: Particularly following the IV induction doses.
• Injection Site Reactions: Redness or minor bruising.

Serious Adverse Events

• Hepatotoxicity: Rare cases of liver injury have occurred; monitoring liver enzymes is recommended in IBD patients.
• Serious Infections: While rare compared to other BIOLOGICS, there is a theoretical risk of TB reactivation or fungal infections.
• Hypersensitivity: Rare cases of anaphylaxis or severe rash.

Research Areas

Direct Clinical Connections

Active research in 2026 is focusing on the “Skin-Gut-Joint” axis. Researchers are investigating if early intervention with Skyrizi in psoriasis patients can prevent the future development of Psoriatic Arthritis by calming systemic IL-23 levels before joint damage begins.

Generalization

The field of TARGETED THERAPY is moving toward “Biosimilar” development and “Bio-better” delivery systems. 2025–2026 trials are evaluating the efficacy of Skyrizi in treating Hidradenitis Suppurativa, a severe inflammatory skin condition, where early results show significant promise in reducing painful nodules.

Severe Disease & Multi-Organ Involvement

Research is tracking the drug’s ability to prevent systemic damage beyond the primary site of inflammation. In Crohn’s disease, this includes its role in reducing the formation of “strictures” (scarring) that often lead to the need for surgery.

Disclaimer: The research discussed regarding the use of Risankizumab for Hidradenitis Suppurativa, pediatric populations, and ankylosing spondylitis is currently in the investigational phase and is not yet applicable to practical or professional clinical scenarios. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A QuantiFERON-TB Gold test and Hepatitis B screening are mandatory.
• Organ Function: Liver Function Tests (LFTs) and a Complete Blood Count (CBC) are established as a baseline.
• Screening: Review of vaccination history. Live vaccines should be avoided at least 4 weeks before starting therapy.

Monitoring and Precautions

• Vigilance: Monitor for signs of infection (fever, persistent cough) and changes in mood or energy.
• Liver Health: For IBD patients, LFTs should be monitored through the 12-week induction period.
• Lifestyle:
  • Sun Protection: While Skyrizi is not specifically photosensitizing, protecting treated skin is recommended.
  • Diet: High-fiber, anti-inflammatory diets are often recommended for IBD patients to support the drug’s action.

Do’s and Don’ts for Immunocompromised Patients:

• DO rotate your injection sites (thigh or abdomen) to prevent skin thickening.
• DO notify your doctor immediately if you develop yellowing of the skin or eyes (jaundice).
• DO stay up to date with inactivated vaccines (like the annual flu shot).
• DON’T receive live-attenuated vaccines (like MMR) while on Skyrizi.
• DON’T stop the medication without a physician-guided plan, as this can lead to a severe disease flare.

Legal Disclaimer

This guide is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. SKYRIZI (risankizumab-rzaa) is a potent TARGETED THERAPY that must be managed by a qualified Dermatologist, Rheumatologist, or Gastroenterologist. Always seek the advice of your physician regarding any medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide.